MEI Pharma reports $23.7M cash, no debt, continues strategic alternatives review

Lite Strategy, Inc.

Cash and cash equivalents $23.7M as of Dec 31, 2024; no outstanding debt.
Strategic alternative evaluation ongoing, including out-licensing and M&A; Oppenheimer & Co. as financial advisor.
Cash preservation efforts underway, including staged reduction-in-force.
No assurance that the strategic review will result in any transaction.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.